ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Rheumatology · RMD Open · 2026-08-20

In 308 adults with DMARD-naïve rheumatoid arthritis, a tailored treat-to-target strategy (first DMARD by autoantibody status, intensification at 1 month) was not superior to routine care: ts/bDMARD use at 10 months 21% vs 17%; mean DAS similar.

RCTn = 308
Looijen et al. Exploring possibilities towards PeRsonalIsed MEdicine in Rheumatoid Arthritis (PRIMERA): tailored modifications to standard treat-to-target management-a multicentre, randomised, open-label trial
Rheumatology · Lancet Rheumatol · 2026-05-20

In 46 adults with systemically active Sjögren's disease (ESSDAI ≥5), leflunomide plus hydroxychloroquine reduced ESSDAI more than placebo at 24 weeks (mean difference −4·135, p=0·0012). Adverse events were similar; one serious event (myocardial infarction) in the treatment group.

RCTn = 46
Wong et al. Repurposing leflunomide and hydroxychloroquine to treat Sjögren's disease (RepurpSS-II): a randomised, double-blind, placebo-controlled, phase 2b trial
Rheumatology · Arthritis Care Res (Hoboken) · 2026-04-02

Systematic review of 19 observational studies of adults on hydroxychloroquine for rheumatic disease: pooled retinopathy prevalence 5.1%; cumulative incidence 0.1% at 5, 2.6% at 10 and 5.6% at 15 years; risk higher with dose >5 mg/kg, CKD, female sex and Asian ethnicity.

Meta-analysisn = 19 studies
Daftarian et al. Risk of Retinopathy Associated with Long-Term Use of Hydroxychloroquine in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.